Search Orphan Drug Designations and Approvals
-
Generic Name: | retifanlimab-dlwr | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Zynyz | ||||||||||||||||
Date Designated: | 10/26/2020 | ||||||||||||||||
Orphan Designation: | Treatment of Merkel cell carcinoma | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Incyte Corporation 1801 Augustine Cut-Off Wilmington, Delaware 19803 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | retifanlimab-dlwr |
---|---|---|
Trade Name: | Zynyz | |
Marketing Approval Date: | 03/22/2023 | |
Approved Labeled Indication: | treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) | |
Exclusivity End Date: | 03/22/2030 | |
Exclusivity Protected Indication* : | treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-